| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 23 | 2024 | 3944 | 3.030 |
Why?
|
| Glioblastoma | 14 | 2023 | 1776 | 2.610 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2024 | 1840 | 2.290 |
Why?
|
| Receptor, ErbB-2 | 13 | 2024 | 2651 | 2.160 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2020 | 1135 | 2.070 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 5 | 2018 | 22 | 2.000 |
Why?
|
| Brain Neoplasms | 16 | 2023 | 4958 | 1.590 |
Why?
|
| Adoptive Transfer | 6 | 2015 | 431 | 1.280 |
Why?
|
| Immunotherapy | 13 | 2019 | 3557 | 1.210 |
Why?
|
| Medulloblastoma | 5 | 2020 | 572 | 0.920 |
Why?
|
| Antigenic Variation | 2 | 2018 | 40 | 0.770 |
Why?
|
| Tumor Escape | 4 | 2016 | 247 | 0.720 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 1580 | 0.680 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 108 | 0.670 |
Why?
|
| Sarcoma | 2 | 2024 | 1838 | 0.670 |
Why?
|
| Liver Diseases | 2 | 2019 | 602 | 0.660 |
Why?
|
| Receptor, EphA2 | 2 | 2018 | 138 | 0.660 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 97 | 0.640 |
Why?
|
| Cerebellar Neoplasms | 3 | 2020 | 478 | 0.580 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 341 | 0.560 |
Why?
|
| Mice, SCID | 9 | 2023 | 1825 | 0.520 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 714 | 0.520 |
Why?
|
| Flow Cytometry | 6 | 2017 | 3045 | 0.520 |
Why?
|
| Cancer Vaccines | 4 | 2020 | 754 | 0.520 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 381 | 0.510 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2017 | 1020 | 0.500 |
Why?
|
| Viral Matrix Proteins | 2 | 2015 | 181 | 0.500 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 105 | 0.490 |
Why?
|
| Microspheres | 1 | 2015 | 238 | 0.480 |
Why?
|
| Tumor Microenvironment | 4 | 2016 | 3031 | 0.480 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 551 | 0.390 |
Why?
|
| Vidarabine | 2 | 2024 | 1383 | 0.380 |
Why?
|
| Chemotaxis | 1 | 2011 | 136 | 0.370 |
Why?
|
| Neoplasms | 6 | 2022 | 15919 | 0.370 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1726 | 0.360 |
Why?
|
| Humans | 59 | 2024 | 270744 | 0.350 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1137 | 0.350 |
Why?
|
| Antigens, Viral | 1 | 2012 | 520 | 0.340 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 92 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 3 | 2014 | 4480 | 0.330 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 2368 | 0.320 |
Why?
|
| Yellow Fever Vaccine | 1 | 2009 | 42 | 0.320 |
Why?
|
| Membrane Proteins | 1 | 2019 | 2929 | 0.320 |
Why?
|
| Yellow Fever | 1 | 2009 | 76 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2023 | 3919 | 0.320 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 496 | 0.300 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 1642 | 0.290 |
Why?
|
| beta-Thalassemia | 1 | 2007 | 33 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 273 | 0.290 |
Why?
|
| Lymphoma | 2 | 2024 | 1520 | 0.270 |
Why?
|
| Child | 18 | 2024 | 30538 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2023 | 7017 | 0.270 |
Why?
|
| Osteosarcoma | 2 | 2015 | 949 | 0.270 |
Why?
|
| Oncogenic Viruses | 1 | 2006 | 24 | 0.270 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 316 | 0.270 |
Why?
|
| Animals | 25 | 2023 | 62045 | 0.260 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 174 | 0.260 |
Why?
|
| Mice | 19 | 2023 | 35594 | 0.260 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1457 | 0.260 |
Why?
|
| Genome, Viral | 1 | 2006 | 189 | 0.250 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1038 | 0.250 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 299 | 0.250 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 404 | 0.240 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 248 | 0.240 |
Why?
|
| Vaccines | 1 | 2010 | 399 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 10385 | 0.240 |
Why?
|
| Graft Rejection | 1 | 2008 | 845 | 0.230 |
Why?
|
| Alemtuzumab | 2 | 2018 | 213 | 0.220 |
Why?
|
| Male | 22 | 2024 | 128374 | 0.220 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 365 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 5759 | 0.220 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2664 | 0.200 |
Why?
|
| Cell Line, Tumor | 11 | 2023 | 14838 | 0.200 |
Why?
|
| Glioma | 4 | 2017 | 1978 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2023 | 897 | 0.190 |
Why?
|
| Antigens, CD19 | 3 | 2021 | 584 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2024 | 33733 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 169 | 0.190 |
Why?
|
| Child, Preschool | 11 | 2024 | 17043 | 0.190 |
Why?
|
| Leukemia | 2 | 2024 | 1719 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2018 | 7237 | 0.190 |
Why?
|
| Transduction, Genetic | 5 | 2020 | 494 | 0.190 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 1955 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 239 | 0.180 |
Why?
|
| Adolescent | 11 | 2024 | 32735 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 372 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 557 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 127 | 0.170 |
Why?
|
| Freezing | 1 | 2019 | 62 | 0.170 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 3243 | 0.170 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 114 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 1655 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 380 | 0.160 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 210 | 0.160 |
Why?
|
| Lymphocyte Activation | 3 | 2016 | 1723 | 0.160 |
Why?
|
| Protein Stability | 1 | 2019 | 377 | 0.160 |
Why?
|
| Transgenes | 2 | 2020 | 576 | 0.150 |
Why?
|
| Female | 17 | 2024 | 148945 | 0.150 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 25 | 0.150 |
Why?
|
| Adult | 9 | 2024 | 81975 | 0.150 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 73 | 0.150 |
Why?
|
| Osteopontin | 1 | 2018 | 145 | 0.150 |
Why?
|
| Immunological Synapses | 1 | 2017 | 31 | 0.150 |
Why?
|
| Ependymoma | 1 | 2020 | 265 | 0.150 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2017 | 32 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2020 | 683 | 0.150 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 111 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 622 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2020 | 1462 | 0.140 |
Why?
|
| Infant | 7 | 2023 | 13985 | 0.140 |
Why?
|
| Vimentin | 1 | 2017 | 255 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 130 | 0.130 |
Why?
|
| Polystyrenes | 1 | 2015 | 36 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2014 | 1714 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2024 | 13414 | 0.130 |
Why?
|
| Protein Multimerization | 1 | 2016 | 232 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 186 | 0.130 |
Why?
|
| Biopsy | 2 | 2020 | 3483 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 1554 | 0.130 |
Why?
|
| Color | 1 | 2015 | 73 | 0.130 |
Why?
|
| Portraits as Topic | 1 | 2015 | 5 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2045 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 2 | 2017 | 960 | 0.120 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 33 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 784 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 276 | 0.120 |
Why?
|
| Cytokines | 3 | 2020 | 2826 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 295 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 284 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 530 | 0.120 |
Why?
|
| Separase | 1 | 2014 | 32 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 436 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2017 | 5697 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 904 | 0.110 |
Why?
|
| Remission Induction | 1 | 2020 | 3652 | 0.110 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 82 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2014 | 65 | 0.110 |
Why?
|
| Protein Binding | 2 | 2020 | 3485 | 0.110 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 26 | 0.110 |
Why?
|
| Adenoviridae | 2 | 2017 | 1497 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 1738 | 0.110 |
Why?
|
| Astrocytes | 1 | 2017 | 405 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2013 | 1050 | 0.110 |
Why?
|
| NFI Transcription Factors | 1 | 2013 | 78 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 422 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2011 | 12102 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 469 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 14616 | 0.110 |
Why?
|
| Middle Aged | 5 | 2024 | 90334 | 0.110 |
Why?
|
| Synapses | 1 | 2017 | 556 | 0.100 |
Why?
|
| Retroviridae | 2 | 2012 | 373 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2020 | 2438 | 0.100 |
Why?
|
| Antibodies | 1 | 2015 | 809 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 121 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 1525 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1320 | 0.100 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 68 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 3043 | 0.090 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 37 | 0.090 |
Why?
|
| Autophagy | 1 | 2017 | 911 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 76 | 0.090 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 428 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1335 | 0.090 |
Why?
|
| Nanoshells | 1 | 2010 | 43 | 0.090 |
Why?
|
| Phototherapy | 1 | 2010 | 83 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 73375 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 610 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 15210 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2024 | 593 | 0.080 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 244 | 0.080 |
Why?
|
| Recurrence | 2 | 2015 | 4875 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 178 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5310 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1712 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 173 | 0.080 |
Why?
|
| CD28 Antigens | 1 | 2009 | 203 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2009 | 252 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2014 | 2422 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2008 | 174 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 175 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 495 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2009 | 259 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6255 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 574 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1388 | 0.070 |
Why?
|
| Survival Rate | 4 | 2017 | 12526 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 140 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 878 | 0.070 |
Why?
|
| Apoptosis | 2 | 2018 | 7754 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2175 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 22216 | 0.070 |
Why?
|
| Brain | 3 | 2018 | 4212 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2196 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3346 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 1032 | 0.070 |
Why?
|
| Carcinoma | 1 | 2017 | 2609 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 286 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2007 | 824 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1188 | 0.060 |
Why?
|
| Models, Biological | 1 | 2013 | 3194 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 700 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2453 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 2902 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 512 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2010 | 2033 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2024 | 39827 | 0.050 |
Why?
|
| Monocytes | 1 | 2007 | 790 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 628 | 0.050 |
Why?
|
| Gene Expression | 2 | 2022 | 3642 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2015 | 9473 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 7915 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 2496 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 45 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10260 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4820 | 0.050 |
Why?
|
| Ghrelin | 1 | 2022 | 71 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 9039 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 719 | 0.050 |
Why?
|
| TRPV Cation Channels | 1 | 2022 | 75 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 7383 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5403 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8696 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 7665 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4223 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 125 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 10706 | 0.040 |
Why?
|
| Biological Products | 1 | 2024 | 319 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2886 | 0.040 |
Why?
|
| Neutropenia | 1 | 2024 | 1006 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2006 | 1253 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 440 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7784 | 0.040 |
Why?
|
| Busulfan | 1 | 2023 | 792 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 870 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 229 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 7894 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2022 | 6398 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 65 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 979 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 38 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2014 | 1857 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 119 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2017 | 40 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 1428 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 5060 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 2808 | 0.040 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2017 | 32 | 0.040 |
Why?
|
| Biotechnology | 1 | 2017 | 77 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 3408 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 104 | 0.030 |
Why?
|
| Antigens | 1 | 2017 | 281 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 418 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2018 | 321 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 189 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 661 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 686 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 12028 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 494 | 0.030 |
Why?
|
| Stem Cell Research | 1 | 2014 | 6 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 14 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 827 | 0.030 |
Why?
|
| Education, Continuing | 1 | 2014 | 34 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 120 | 0.030 |
Why?
|
| Genetic Research | 1 | 2014 | 66 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 197 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 885 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 4255 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 220 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 6525 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 657 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 507 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 345 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 965 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 757 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 252 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 1366 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 30 | 0.020 |
Why?
|
| Seizures | 1 | 2017 | 1035 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2010 | 55 | 0.020 |
Why?
|
| Microvilli | 1 | 2010 | 88 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3845 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 286 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 158 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 239 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 460 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 929 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 889 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4829 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 3028 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 1180 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 2137 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 659 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1121 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 387 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 22480 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1960 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 6237 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 9041 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5825 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1414 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3604 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 90 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 480 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 84 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2007 | 286 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 2454 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2007 | 228 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2455 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 3063 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 1095 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 1419 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15911 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17896 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 1110 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 13021 | 0.010 |
Why?
|
| United States | 1 | 2014 | 15853 | 0.010 |
Why?
|